For Healthcare Professionals

Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts


About the study

A study to evaluate the safety, efficacy and tolerability of remibrutinib at three doses versus placebo in adult participants who have a confirmed allergy to peanuts. The efficacy will be measured by the ability of participants to tolerate increasing doses of peanut protein during an oral food challenge after 1 month of study treatment.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Medical History of allergy to peanuts
  2. Positive peanut IgE >= 0.35 kUA/L
  3. Positive Skin Prick test for peanut allergen during screening for study
  4. Positive Oral Food Challenge to peanut during screening for study
  5. Willingness to comply with study schedule and procedures and avoid other allergens during study period


Exclusion Criteria:

  1. History of severe or life-threatening hypersensitivity event leading to ICU admission or intubation within 60 days of screening
  2. Uncontrolled asthma
  3. Bleeding risk or coagulation disorder(s)
  4. Use of anticoagulants or anti-platelets (aspirin or clopidogrel may be permitted)
  5. History of splenectomy
  6. Any significant disease that would put the safety of the patient at risk. This includes, but is not limited to: history of cancer, significant cardiac disease/history, hematology disorders, history of GI bleeding, active infectious process, liver disease, renal disease, immunologic disease (stable diabetes and thyroid disease may be permitted), alcohol or drug abuse, etc.

Other protocol-defined inclusion/exclusion criteria may apply.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Allergy, Peanut

Age (in years)

18 - 55


Phase 2

Participants needed


Est. Completion Date

Apr 29, 2026

Treatment type



Novartis identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.